Adjusted outcomes for DLBCL patients undergoing auto-HCT in PR receiving platinum-based salvage regimens as second-line therapy
| Outcomes . | No ECF (n = 40) . | ECF (n = 80) . | P . |
|---|---|---|---|
| NRM | |||
| 1-y | 5.1 (0.9-15.3) | 7.5 (3-14.7) | .60 |
| 3-y | 7.7 (1.9-18.9) | 9.1 (4-17) | .79 |
| 5-y | 7.7 (1.9-18.9) | 9.1 (4-17) | .79 |
| Progression or relapse | |||
| 1-y | 32.8 (18.8-47.7) | 42.5 (31.5-53.1) | .31 |
| 3-y | 54.5 (37-69) | 48.2 (36.6-58.9) | .53 |
| 5-y | 58.3 (40-72.8) | 56.8 (43.7-67.9) | .88 |
| PFS | |||
| 1-y | 65.9 (52-79.9) | 48.4 (37-59.1) | .05 |
| 3-y | 43.8 (28.8-58.9) | 48.2 (30.4-51.7) | .77 |
| 5-y | 40.4 (25.1-55.8) | 32.7 (21.7-43.7) | .42 |
| OS | |||
| 1-y | 81.4 (69.8-93) | 60.1 (49.4-70.8) | .01 |
| 3-y | 68.5 (54.3-82.8) | 49.6 (38.4-60.7) | .04 |
| 5-y | 59.4 (43.6-75.1) | 47.2 (35.8-58.7) | .22 |
| Outcomes . | No ECF (n = 40) . | ECF (n = 80) . | P . |
|---|---|---|---|
| NRM | |||
| 1-y | 5.1 (0.9-15.3) | 7.5 (3-14.7) | .60 |
| 3-y | 7.7 (1.9-18.9) | 9.1 (4-17) | .79 |
| 5-y | 7.7 (1.9-18.9) | 9.1 (4-17) | .79 |
| Progression or relapse | |||
| 1-y | 32.8 (18.8-47.7) | 42.5 (31.5-53.1) | .31 |
| 3-y | 54.5 (37-69) | 48.2 (36.6-58.9) | .53 |
| 5-y | 58.3 (40-72.8) | 56.8 (43.7-67.9) | .88 |
| PFS | |||
| 1-y | 65.9 (52-79.9) | 48.4 (37-59.1) | .05 |
| 3-y | 43.8 (28.8-58.9) | 48.2 (30.4-51.7) | .77 |
| 5-y | 40.4 (25.1-55.8) | 32.7 (21.7-43.7) | .42 |
| OS | |||
| 1-y | 81.4 (69.8-93) | 60.1 (49.4-70.8) | .01 |
| 3-y | 68.5 (54.3-82.8) | 49.6 (38.4-60.7) | .04 |
| 5-y | 59.4 (43.6-75.1) | 47.2 (35.8-58.7) | .22 |
Includes ifosfamide, carboplatin, etoposide; gemcitabine-dexamethasone-cisplatin; gemcitabine-oxaliplatin; and dexamethasone, cytarabine, cisplatin chemotherapy regimens. Data are percentage probability (95% CI). Bold values are statistically significant P values.